Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Smartwatch and app could keep liver patients out of hospital

NCT ID NCT06223893

Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a home monitoring system called CirrhoCare can help people with decompensated cirrhosis avoid unplanned hospital visits. Participants use an Apple Watch, iPhone app, and Bluetooth devices to track their health at home. The trial will compare this approach to standard care in 214 adults over 90 days after hospital discharge.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CirrhoCare digital home monitoring system (includes Apple Watch, iPhone app, Bluetooth blood pressure monitor, scale, and thermometer)
What this could lead to
If it works, this could provide a way for patients with advanced liver disease to be monitored at home, potentially reducing hospital stays and improving quality of life.
What could go wrong
This is a relatively small trial (214 people) testing a device, not a drug. The benefits may be modest, and the system may not work for everyone or could be difficult to use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 214 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: 1. Adults ≥ 18 years and diagnosed with cirrhosis of any aetiology. 2. Cirrhosis defined by standard clinical criteria, ultrasonographic findings and/or histology. Cirrhosis of any aetiology may be included. However, participants with cirrhosis due to autoimmune hepatitis must be on a stable corticosteroid dose for ≥3-month period before study inclusion (to be recorded on concomitant log). 3. Cirrhosis severity-risk defined by European-Foundation Consortium Liver Failure - Acute Decompensation score (CLIF-C AD score) ≥42 points but ≤65 points at the time of screening. 4. Hospitalisation for acute decompensation \[determined as one or more of the following: increasing ascites, variceal haemorrhage, overt hepatic encephalopathy, spontaneous bacterial peritonitis (SBP) or hepatorenal syndrome - acute kidney injury (HRS-AKI)\]. 5. Participants able to give informed consent. Exclusion criteria: 1. Participants with ACLF grade 2 and above according to the criteria published by Moreau 2. Participants with CLIF-C AD score ≥ 66, who have a high mortality similar to ACLF ≥2 participants. 3. Current overt hepatic encephalopathy, defined as grade II-IV hepatic encephalopathy according to the West-Haven classification, unable to give consent. 4. Participants with active hepatocellular carcinoma (HCC) or history of HCC that is in remission for less than six months for uninodular HCC or for less than 12 months for multinodular HCC within Milan criteria. 5. Participants with a history of significant extra hepatic disease with impaired short-term prognosis, including congestive heart failure New York Heart Association Grade III/IV, COPD GOLD \>2, chronic kidney disease with serum creatinine \>2mg/dL or under renal replacement therapy. 6. Participants with documented refractory ascites on a palliative pathway. 7. Participants who are active on the transplant waiting list. 8. Participants with current extra hepatic malignancies including solid tumours and hematologic disorders. 9. Participants with mental incapacity, significant language barriers, or any other reason considered by the investigator precluding adequate understanding, cooperation or compliance in the study. 10. Participants with active viral infections, or yet to achieve clear response to anti-viral therapy. 11. Any disorders likely to impact on study engagement, including severe frailty, severe addiction history (including opioids) with evidence of multiple recent relapses. 12. Any other reason that the PI considers would make the participant unsuitable to enter CirrhoCare (e.g., participants on an end-of-life palliative care pathway). 13. Participants enrolled in other interventional trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decompensated cirrhosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    15 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Derriford Hospital, University Hospitals Plymouth NHS Trust

    RECRUITING

    Plymouth, PL6 8DH, United Kingdom

  • John Radcliff Hospital, Oxford University Hospitals NHS Foundation Trust

    RECRUITING

    Oxford, OX3 9DU, United Kingdom

  • King's College Hospital, King's College Hospital NHS Foundation Trust

    RECRUITING

    London, SE5 9RS, United Kingdom

  • Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Foundation Trust

    RECRUITING

    Birmingham, B15 2GW, United Kingdom

  • Queen's Medical Centre, Nottingham University Hospitals NHS Trust

    RECRUITING

    Nottingham, NG7 2UH, United Kingdom

  • Royal Free Hospital, Royal Free London NHS Foundation Trust

    RECRUITING

    London, NW3 2QG, United Kingdom

  • Royal Liverpool University Hospital, Liverpool University Hospitals NHS Foundation Trust

    RECRUITING

    Liverpool, L7 8YE, United Kingdom

  • Royal Sussex County Hospital, University Hospitals Sussex NHS Foundation Trust

    RECRUITING

    Brighton, BN2 5BE, United Kingdom

  • Southampton General Hospital, University Hospital Southampton NHS Foundation Trust

    RECRUITING

    Southampton, SO16 6YD, United Kingdom

  • St George's Hospital, St George's university Hospital NHS Foundation Trust

    RECRUITING

    London, SW17 0QT, United Kingdom

  • St Thomas Hospital, Liverpool University Hospitals NHS Foundation Trust

    NOT_YET_RECRUITING

    London, SE1 7EH, United Kingdom

  • The Royal London Hospital, Barts Health NHS Trust

    RECRUITING

    London, E1 1FR, United Kingdom

  • Torbay Hospital, Torbay and South Devon NHS Foundation Trust

    RECRUITING

    Torquay, TQ2 7AA, United Kingdom

  • Walsgrave General Hospital, University Hospital Coventry & Warwickshire NHS Trust

    RECRUITING

    Coventry, CV2 2DX, United Kingdom

  • Whittington Hospital, Whittington Health NHS Trust

    RECRUITING

    London, N19 5NF, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.